

From: [REDACTED]
Sent: 23 April 2008 14:46
To: Natalie Bemrose
Cc: [REDACTED]
Subject: Two Health Technology Appraisals: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, and; Alendronate, etidronate, risedronate, raloxifene, stro

Dear Natalie

Thank you for the opportunity to comment on two Appraisal Consultation Documents and the Evaluation Report for the above appraisals.

I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.

Many thanks and best wishes

[REDACTED]
NICE Liaison Team
Department of Health

- - Disclaimer - -

This e-mail and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received.

Incoming and outgoing e-mail messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's e-mail policy click here <http://www.dh.gov.uk/terms>

The original of this email was scanned for viruses by the Government Secure Intranet virus scanning service supplied by Cable&Wireless in partnership with MessageLabs. (CCTM Certificate Number 2007/11/0032.) On leaving the GSi this email was certified virus free. Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.

Delivered via MessageLabs
